The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As a leading academic medical center and research institution, Massachusetts General Hospital has expertise in conducting high-level biomedical research, including clinical trials, laboratory studies, and medical countermeasure development across a range of disease areas. This award leverages the hospital's specialized facilities and research capabilities to advance the understanding and treatment of ovarian cancer.